On this page
Deep Dive — Evidence Details
Bottom Line
- ▸Beta-lactam plus macrolide combination therapy is preferred over doxycycline combinations for hospitalized patients due to lower mortality [11].
- ▸Adjunctive low-dose hydrocortisone (≤400 mg/day) reduces mortality in severe CAP but increases risks of hyperglycemia and rehospitalization [4, 12, 45].
- ▸Antibiotic therapy can be safely discontinued after 3 days in patients who achieve clinical stability [15, 29].
First-line empiric therapy for community-acquired pneumonia (CAP) in adults without risk factors for resistant pathogens consists of a (e.g., , ) combined with a (e.g., , ) or monotherapy with a respiratory (e.g., ) [6]A1c[44]D5. In hospitalized patients, plus a is associated with lower 90-day mortality (HR 0.83, 95% CI 0.73-0.95) compared to plus a [11]B2b. For severe CAP requiring ICU admission, adjunctive 200 mg daily reduces 28-day mortality (6.2% vs 11.9%; absolute difference -, 95% CI -9.6 to -1.7; NNT = 18 to prevent one death) [12]A1b[45]D5.
Empiric Regimen Selection
Empiric coverage for methicillin-resistant ( ) or is not routinely recommended unless specific local risk factors or prior isolation of these pathogens exist [6]A1c[49]D5. In non-ICU patients, 600 mg every 12 hours demonstrated superior clinical cure rates compared to 1-2 g every 24 hours (OR 1.66, 95% CI 1.34-2.06) [10]A1a. Novel agents such as and are non-inferior to and provide alternatives for multidrug-resistant pathogens [14]A1b[38]B2a[51]D5.
Treatment Duration and Stability
Short-course therapy (3-5 days) is non-inferior to 7-10 days for patients who achieve clinical stability within 48-72 hours [3]B2a[15]A1b[16]B2a. In a randomized trial of hospitalized patients stable at day 3, discontinuing was non-inferior to an additional 5 days of therapy (cure rate 77% vs 68%; difference 9.42%, 95%) [15]A1b.
Pearl: Empiric / combinations remain the standard for hospitalized CAP, with adjunctive significantly reducing mortality in severe cases [11]B2b[12]A1b[44]D5. (High, multiple RCTs and meta-analyses)
Background: Evolution of Treatment
- ▸Short-course antibiotic therapy (3-5 days) is non-inferior to traditional 7-10 day courses in patients achieving clinical stability [15, 16, 18].
- ▸Low-dose corticosteroids (≤400 mg hydrocortisone equivalent) significantly reduce mortality in severe CAP, with an NNT of 18 [12, 45].
- ▸Serum procalcitonin lacks the sensitivity (0.55) and specificity (0.76) required to safely guide the withholding of antibiotics in CAP [1].
The of community-acquired pneumonia (CAP) has transitioned from a reliance on prolonged, broad-spectrum monotherapy toward evidence-based, shorter-course regimens and personalized adjunctive therapies. Historically, monotherapy with , , or second-generation cephalosporins was the standard for hospitalized patients [66]B2a. This approach was challenged by the recognition of atypical pathogens like and , leading to guidelines that favored combining a beta-lactam with a macrolide or using fluoroquinolone monotherapy [66]B2a[79]D5.
Pivotal Shifts in Antibiotic Strategy
The transition to shorter treatment durations was driven by evidence that prolonged courses did not improve outcomes and increased resistance [16]B2a. The PTC trial (2021) demonstrated that discontinuing beta-lactam therapy after 3 days in clinically stable, non-ICU patients was non-inferior to an additional 5-day course (cure rate 77% vs 68%; difference 9.42%, 95%) [15]A1b. Similarly, the CAP-IT trial (2021) in children found that 3 days of was non-inferior to 7 days regarding antibiotic re-treatment (12.5% vs 12.5%; difference 0.1%, 1-sided 95% CI -∞ to 3.9) [18]A1b.
Evolution of Adjunctive Therapy
The role of corticosteroids has been a major point of historical contention. While early studies were inconsistent, the CAPE COD trial (2023) established that intravenous 200 mg daily reduced 28-day mortality in severe CAP (6.2% vs 11.9%; absolute difference -, 95% CI -9.6 to -1.7; NNT = 18 to prevent one death) [12]A1b[45]D5.
Abandoned and Emerging Approaches
Pearl: Modern CAP management emphasizes clinical stability as the primary driver for treatment duration, with 3-day courses proven non-inferior to longer regimens in stable patients [15]A1b[18]A1b. Adjunctive hydrocortisone is now a standard consideration for severe CAP to reduce mortality [12]A1b[45]D5.
| Era | Primary Strategy | Key Evidence | Outcome |
|---|---|---|---|
| Historical | Prolonged (7-14d) beta-lactam monotherapy | Traditional practice [66]B2a | High resistance, longer LOS |
| Transition | Beta-lactam + Macrolide or Fluoroquinolone | IDSA/ATS Guidelines [79]D5[80]D5 | Improved coverage of atypicals |
| Modern | Short-course (3-5d) + Adjunctive Steroids | PTC [15]A1b, CAPE COD [12]A1b | Reduced mortality and antibiotic exposure |
Current Evidence and Standard
- ▸Beta-lactam plus macrolide combination therapy remains the standard for hospitalized patients without MDRO risk factors.
- ▸Short-course therapy (3-5 days) is effective for both adults and children who reach clinical stability within 72 hours.
- ▸Adjunctive low-dose corticosteroids (≤400 mg hydrocortisone equivalent) reduce mortality in severe CAP but increase hyperglycemia risk.
Empiric therapy for community-acquired pneumonia (CAP) centers on covering typical pathogens like Streptococcus pneumoniae and atypical organisms. For hospitalized patients without risk factors for resistant bacteria, standard first-line therapy is a / combination, such as plus , for a minimum of 3 days [44]D5.
Pivotal Comparative Evidence
Recent evidence supports the use of newer agents and shorter durations for non-severe cases. In the SOLITAIRE-ORAL trial, the novel macrolide (800 mg day 1, then 400 mg days 2-5) was non-inferior to (400 mg for 7 days) in early clinical response (vs; difference 0.29, 95%) [9]A1b. Similarly, the OPTIC trial found (100 mg IV every 12-24 hours, then 300 mg orally) non-inferior to (400 mg) for early clinical response (81.1% vs 82.7%; difference -1.6, 95% CI -7.1 to 3.8) [14]A1b.
For hospitalized patients, fosamil (600 mg every 12 hours) demonstrated superiority over (1-2 g every 24 hours) in a meta-analysis of PORT risk class 3-4 patients (OR 1.66, 95% CI 1.34-2.06) [10]A1a. Regarding dosing, a large retrospective study found no difference in 30-day mortality between 1 g and 2 g daily (4.6% vs 4.5%), though the 2 g dose was associated with lower mortality in patients requiring mechanical ventilation (17.2% vs 20.4%; RD -, 95% CI - to -; NNT = 32) [28]B2b.
Treatment Duration and De-escalation
Short-course therapy (3-6 days) is increasingly supported for patients achieving clinical stability. A meta-analysis of 21 trials found that treatment for ≤6 days resulted in lower mortality than longer courses (RR 0.52, 95% CI 0.33-0.82) [16]B2a. In the PTC trial, discontinuing therapy after 3 days in stable patients was non-inferior to an additional 5 days of treatment (cure rate 77% vs 68%; difference 9.42%, 95%) [15]A1b. For pediatric outpatients, 3-5 days of was as effective as 7-10 days (RD 0.1%, 95% CI -3.0% to 2.0%) [3]B2a.
Adjunctive Therapies
Corticosteroids are recommended for severe CAP to reduce mortality and time to stability. The CAPE COD trial found that IV (200 mg daily) reduced 28-day mortality in ICU patients compared to placebo (6.2% vs 11.9%; absolute difference -, 95% CI -9.6 to -1.7; NNT = 18) [12]A1b. However, corticosteroids increase the risk of hyperglycemia (aOR 2.15) and CAP-related rehospitalization (aOR 1.85) [4]B2a.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Antibiotics for viral CAP | ATS 2025: Treat all hospitalized patients even if viral assay is positive [25]D5[29]A1c. | IDSA: Withhold antibiotics in non-severe cases with positive viral assays and no evidence of coinfection [24]D5[91]D5. | Moderate | IDSA declined to endorse ATS 2025 update due to stewardship concerns. |
| Doxycycline vs Macrolide | associated with lower mortality than in matched cohorts [11]B2b. | No significant difference in mortality or LOS in ICU-specific prospective cohorts [56]D5. | Low | remains a recommended alternative but evidence is mixed. |
Pearl: Short-course antibiotic therapy (3-5 days) is non-inferior to longer durations in patients who achieve clinical stability, and adjunctive reduces 28-day mortality in severe CAP with an NNT of 18 [12]A1b[15]A1b[16]B2a.
| Drug | Comparator | Outcome (Early Clinical Response) | Result [N] |
|---|---|---|---|
| 78.2% vs 77.9% | Non-inferior [9]A1b | ||
| 81.1% vs 82.7% | Non-inferior [14]A1b | ||
| Comparable efficacy | Non-inferior [38]B2a[90]D5 | ||
| Clinical cure (MITT) | Superior (OR 1.66) [10]A1a |
Applicability and Caveats
- ▸Short-course antibiotic therapy (3-5 days) is effective for both pediatric and adult CAP patients who reach clinical stability.
- ▸Broad-spectrum antibiotics increase adverse event risks in otherwise healthy outpatients compared to narrow-spectrum options.
- ▸Early IV-to-oral switch by day 3 reduces hospital stay and costs without compromising safety.
The clinical utility of empiric regimens depends on the patient's age, comorbidities, and the ability to transition to oral therapy. While standard durations often reach 7 to 10 days, evidence supports shorter courses for both adults and children who achieve clinical stability [3]B2a[16]B2a[104]B2a.
Pediatric Considerations and Dosing
In children aged 6 months and older with nonsevere CAP, a 3 to 5 day antibiotic course is as effective as 7 to 10 days [3]B2a[105]B2a. The CAP-IT trial demonstrated that lower-dose (35-50 mg/kg/d) is noninferior to higher doses (70-90 mg/kg/d) regarding the need for re-treatment within 28 days (12.6% vs 12.4%; difference 0.2%, 95% CI -inf to 4.0%) [18]A1b. Shorter 3-day courses were also noninferior to 7-day courses (12.5% vs 12.5%; difference 0.1%, 95% CI -inf to 3.9%) [18]A1b. However, 3-day treatment was associated with a longer median duration of cough (12 vs 10 days; HR 1.2, 95% CI 1.0-1.4) [18]A1b.
Comorbidities and Risk Stratification
Empiric therapy must be adjusted for specific patient factors:
- Diabetes Mellitus: In elderly patients with type 2 diabetes and CAP, continuous subcutaneous insulin infusion improved clinical outcomes and reduced inflammatory markers more effectively than multiple daily injections [108]A1b.
- Healthy Adults: In outpatients without comorbidities, broad-spectrum regimens (e.g., or beta-lactams) increase the risk of adverse events compared to monotherapy [98]D5. Beta-lactams specifically increased risks for nausea, vomiting, and non-Clostridioides difficile diarrhea (RD 4.61 per 1000) [98]D5.
- Viral Coinfection: The IDSA has expressed concern regarding the 2025 ATS update, noting that routine for outpatients with positive viral tests and no comorbidities may confer more risk than benefit [24]D5.
Transition and Stewardship
Early transition from intravenous to oral therapy (by hospital day 3) is associated with shorter length of stay and lower costs without increasing 14-day mortality [23]D5. Despite this, early switching occurs in only 6% of cases [23]D5. At discharge, approximately 70% of patients receive excessive antibiotic durations, with a median total length of therapy of 9.5 days [101]D5.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Antibiotics in viral CAP | ATS 2025: Suggests withholding in healthy outpatients [29]A1c. | IDSA: Recommends individualized decision-making; warns against nondiscriminatory use [24]D5. | Low quality evidence | Risk of bacterial coinfection vs. antibiotic harm. |
| Dosing | 1 g daily is sufficient for routine CAP [28]B2b. | 2 g daily preferred for severe CAP requiring mechanical ventilation [28]B2b. | Retrospective cohort | 2 g reduced 30-day mortality in ventilated patients (17.2% vs 20.4%) [28]B2b. |
Pearl: Short-course therapy (3-5 days) is noninferior to standard 7-10 day courses in both adults and children who achieve clinical stability [3]B2a[16]B2a[104]B2a. In children, lower-dose amoxicillin (35-50 mg/kg/d) is noninferior to higher doses for preventing re-treatment [18]A1b.
| Regimen | 30-Day Mortality (Routine) | 30-Day Mortality (Ventilated) | Adverse Events |
|---|---|---|---|
| Ceftriaxone 1 g | 4.6% | 20.4% | 1.8% |
| Ceftriaxone 2 g | 4.5% | 17.2% | 1.9% |
On the Horizon
- ▸Short-course antibiotic therapy (3-5 days) is non-inferior to longer courses in pediatric CAP and is being evaluated in adults.
- ▸Adjunctive hydrocortisone reduces 28-day mortality in severe CAP with an NNT of approximately 18.
- ▸Rapid multiplex PCR testing significantly improves antimicrobial stewardship by identifying viral etiologies in the emergency department.
Recent evidence is challenging traditional paradigms regarding the duration, route, and adjunctive of community-acquired pneumonia (CAP). While current guidelines often suggest 5 to 7 days of therapy, meta-analyses in pediatric populations demonstrate that short-course treatment of 3 to 5 days is equally effective as 7 to 10 days, with a risk difference for treatment failure of only 0.1% (95% CI, -3.0% to 2.0%) [3]B2a. Similarly, in high-risk pediatric settings, extending therapy to 13-14 days provided no benefit in preventing long-term respiratory sequelae compared to standard 5-6 day courses (RR 1.02, 95% CI 0.85-1.22) [119]A1b. For hospitalized adults, post-hoc analyses suggest that exclusive oral therapy may be non-inferior to initial intravenous (IV) administration, with no significant difference in 15-day failure rates (aOR 0.973) [120]A1b.
Adjunctive Corticosteroids
Systemic are emerging as a potential standard for severe CAP. A 2023 meta-analysis of 15 trials found that adjunctive steroids significantly reduced 30-day all-cause mortality (6.15% vs 9.06%; RR 0.67, 95% CI 0.53-0.85; NNT = 35) [110]B2a. The CAPE COD trial specifically demonstrated that IV (200 mg daily) reduced 28-day mortality in ICU patients from 11.9% to 6.2% (absolute difference -; NNT = 18) [12]A1b.
Novel Agents and Diagnostics
Newer antimicrobials and rapid diagnostics aim to refine empiric coverage:
- : This pleuromutilin maintains >99% susceptibility against S. pneumoniae and S. aureus, including strains resistant to macrolides and fluoroquinolones [122]D5.
- : A novel non-fluorinated quinolone (500 mg IV daily) demonstrated non-inferiority to with a clinical cure rate of 91.8% [118]A1b.
- Multiplex PCR: Rapid syndromic panels in pediatric emergency departments improved treatment appropriateness (68.6% vs 48.2%) primarily by reducing unnecessary antibiotic use in viral cases [117]A1b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Macrolide Add-on | Routine use in all hospitalized CAP [44]D5 | No mortality benefit over BL monotherapy [114]A1a | Moderate | May limit macrolides to severe cases |
| Steroid Use | Recommended in severe CAP to reduce mortality [12]A1b[45]D5 | Potential for hyperglycemia and secondary infection [45]D5 | High | Requires careful patient selection |
| MRSA Coverage | Use generic risk factors (e.g., prior MRSA) [111]D5 | Use machine learning/local validation [46]D5[111]D5 | Emerging | Local validation reduces ESA overuse by 38.8% |
Pearl: Adjunctive low-dose hydrocortisone (200 mg/day) is now supported by high-level evidence to reduce mortality in severe CAP requiring ICU admission [12]A1b[110]B2a.
| Intervention | Key Finding | Evidence Source |
|---|---|---|
| Reduced 28-day mortality in severe CAP (RR 0.67) | [12]A1b[110]B2a | |
| Non-inferior to levofloxacin; 91.8% cure rate | [118]A1b | |
| >99% susceptibility against resistant S. pneumoniae | [122]D5 | |
| Multiplex PCR | Increased treatment appropriateness (RR 1.42) | [117]A1b |
References
- [1]
Kamat IS, Ramachandran V, Eswaran H et al.. “Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31241140 ↗
L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [2]
Jasper AS, Musuuza JS, Tischendorf JS et al.. “Are Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32296816 ↗
L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [3]
Kuitunen I, Jääskeläinen J, Korppi M et al.. “Antibiotic Treatment Duration for Community-Acquired Pneumonia in Outpatient Children in High-Income Countries-A Systematic Review and Meta-Analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 35579504 ↗
L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon - [4]
Briel M, Spoorenberg SMC, Snijders D et al.. “Corticosteroids in Patients Hospitalized With Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Metaanalysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2018). PMID: 29020323 ↗
L2SR_OBSCited in: Bottom Line, Current Evidence and Standard - [5]
Folgori L, Bielicki J, Ruiz B et al.. “Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review.” The Lancet. Infectious diseases (2016). PMID: 27375212 ↗
L2TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [6]
Metlay JP, Waterer GW, Long AC et al.. “Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.” American journal of respiratory and critical care medicine (2019). PMID: 31573350 ↗
L2GUIDELINECited in: Bottom Line - [7]
Jones BE, Ramirez JA, Oren E et al.. “Diagnosis and Management of Community-acquired Pneumonia: An Official American Thoracic Society Clinical Practice Guideline.” American journal of respiratory and critical care medicine (2026). PMID: 40679934 ↗
L2GUIDELINECited in: Bottom Line - [8]
Schweitzer VA, van Heijl I, Boersma WG et al.. “Narrow-spectrum antibiotics for community-acquired pneumonia in Dutch adults (CAP-PACT): a cross-sectional, stepped-wedge, cluster-randomised, non-inferiority, antimicrobial stewardship intervention trial.” The Lancet. Infectious diseases (2021). PMID: 34627499 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [9]
Barrera CM, Mykietiuk A, Metev H et al.. “Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).” The Lancet. Infectious diseases (2016). PMID: 26852726 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats - [10]
Taboada M, Melnick D, Iaconis JP et al.. “Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.” The Journal of antimicrobial chemotherapy (2015). PMID: 26702925 ↗
L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [11]
Odeyemi YE, Tekin A, Schanz CC et al.. “Comparative Effectiveness of Azithromycin Versus Doxycycline in Hospitalized Patients With Community-Acquired Pneumonia Treated With Beta-Lactams: A Multicenter Matched Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 40378193 ↗
L3COHORTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [12]
Dequin PF, Meziani F, Quenot JP et al.. “Hydrocortisone in Severe Community-Acquired Pneumonia.” The New England journal of medicine (2023). PMID: 36942789 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon - [13]
Lucinde RK, Gathuri H, Mwaniki P et al.. “A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia.” The New England journal of medicine (2025). PMID: 41159889 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [14]
Stets R, Popescu M, Gonong JR et al.. “Omadacycline for Community-Acquired Bacterial Pneumonia.” The New England journal of medicine (2019). PMID: 30726692 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [15]
Dinh A, Ropers J, Duran C et al.. “Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.” Lancet (London, England) (2021). PMID: 33773631 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [16]
Tansarli GS, Mylonakis E. “Systematic Review and Meta-analysis of the Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults.” Antimicrobial agents and chemotherapy (2018). PMID: 29987137 ↗
L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats - [17]
Giamarellos-Bourboulis EJ, Kotsaki A, Kotsamidi I et al.. “Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial.” JAMA (2026). PMID: 41359996 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [18]
Bielicki JA, Stöhr W, Barratt S et al.. “Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial.” JAMA (2021). PMID: 34726708 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats - [19]
Tannous A, Levinson SL, Bolognese J et al.. “Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin in Patients Hospitalized for Nonsevere Community-Acquired Pneumonia.” Antimicrobial agents and chemotherapy (2020). PMID: 32690640 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [20]
Groeneveld GH, van der Reyden TJ, Joosten SA et al.. “Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial.” The Journal of antimicrobial chemotherapy (2019). PMID: 31106377 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [21]
Chen YC, Hsu WY, Chang TH. “Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia.” Emerging infectious diseases (2020). PMID: 32568052 ↗
L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [22]
Wu H, Cheng Z, Ding F et al.. “Evaluation of the clinical efficacy, safety, and permeability in pulmonary epithelial lining fluid of contezolid, a novel oxazolidinone drug, in adult patients with pneumonia.” Antimicrobial agents and chemotherapy (2026). PMID: 41778914 ↗
L2TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard - [23]
Deshpande A, Klompas M, Guo N et al.. “Intravenous to Oral Antibiotic Switch Therapy Among Patients Hospitalized With Community-Acquired Pneumonia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37011018 ↗
L5OTHERCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon - [24]
Klompas M, Al-Hasan M, Al Mohajer M et al.. “Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA Did Not Endorse the Community-Acquired Pneumonia Guidelines 2025 Update.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41340493 ↗
L5OTHERCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats - [25]
Biebelberg B, Chen T, McKenna C et al.. “Associations Between Antibiotic Use and Outcomes in Patients Hospitalized With Community-Acquired Pneumonia and Positive Respiratory Viral Assays.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41378862 ↗
L5OTHERCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [26]
Ambroggio L, Cotter J, Hall M et al.. “Management of Pediatric Pneumonia: A Decade After the Pediatric Infectious Diseases Society and Infectious Diseases Society of America Guideline.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37352841 ↗
L5OTHERCited in: Bottom Line, Current Evidence and Standard, On the Horizon - [27]
Saravolatz L, Gandhi TN, Vaughn VM et al.. “Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 40601818 ↗
L5OTHERCited in: Bottom Line, Current Evidence and Standard - [28]
Taniguchi J, Aso S, Matsui H et al.. “Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study.” The Journal of antimicrobial chemotherapy (2025). PMID: 40492536 ↗
L3COHORTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats - [29]
Long B, Gottlieb M. “2025 guideline updates for community-acquired pneumonia diagnosis and management.” The American journal of emergency medicine (2026). PMID: 42127879 ↗
L2GUIDELINECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats - [30]
Potter-Schwartz L, Swe MM, Sharland M et al.. “Effectiveness of amoxicillin and amoxicillin-clavulanate for the treatment of community-acquired pneumonia in adults and children: a systematic review and meta-analysis.” BMJ open (2026). PMID: 42097647 ↗
L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [31]
Nasr R, Rahman AA, ElHadi N et al.. “Macrolides usage as anti-inflammatory agents in the treatment of community-acquired pneumonia and ventilator-associated pneumonia: a systematic review and meta-analysis.” Systematic reviews (2026). PMID: 42087250 ↗
L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [32]
Laterre PF, Colin G, Dequin PF et al.. “CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.” The Lancet. Infectious diseases (2019). PMID: 31056427 ↗
L5OTHERCited in: Bottom Line, Current Evidence and Standard - [33]
Hashmi M, Haniffa R, Jayakumar D et al.. “Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).” Critical care medicine (2026). PMID: 42101205 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [34]
Pereira PC, de Lima CJ, Fernandes AB et al.. “Effects of photobiomodulation by infrared LED-therapy on improving cardiopulmonary functions and hematologic parameters in patients with community-acquired pneumonia (CAP).” Respiratory medicine (2026). PMID: 42009264 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [35]
Stylianakis E, Kakavoulis N, Foutadakis S et al.. “Molecular pathways driving clarithromycin benefit in community-acquired pneumonia: analysis of the ACCESS randomised trial.” EBioMedicine (2026). PMID: 41934919 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [36]
Michels EHA, Dequin PF, Butler JM et al.. “Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlled trial.” The Lancet. Respiratory medicine (2026). PMID: 41856148 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [37]
Pinot J, Delory T, Pétrier M et al.. “Clinical data, chest X-ray or C-reactive protein to initiate antibiotic therapy in outpatients with suspected community-acquired pneumonia: a prospective, randomized, controlled, digital case vignette study.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2026). PMID: 41839418 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats - [38]
Wu M, Han S, Li H. “Lefamulin versus omadacycline for community acquired bacterial pneumonia: a systematic review and anchored indirect treatment comparison using moxifloxacin as the common comparator.” Journal of comparative effectiveness research (2026). PMID: 41823576 ↗
L2SR_OBSCited in: Bottom Line, Current Evidence and Standard - [39]
Takeda K, Takazono T, Ashizawa N et al.. “Lascufloxacin switch therapy versus ampicillin/sulbactam for older patients with community-acquired pneumonia in Japan (STEP study): a study protocol for a multicentre open-label randomised controlled non-inferiority trial.” BMJ open (2026). PMID: 42379706 ↗
L2TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard - [40]
Reyes LF, Conway Morris A, Serrano-Mayorga C et al.. “Community-acquired pneumonia.” Lancet (London, England) (2025). PMID: 41110447 ↗
L5REVIEW_NARRATIVECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [41]
Aliberti S, Dela Cruz CS, Amati F et al.. “Community-acquired pneumonia.” Lancet (London, England) (2021). PMID: 34481570 ↗
L5REVIEW_NARRATIVECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [42]
Huang L, Price EP, Sarovich DS et al.. “Bacteremia and Community-Acquired Pneumonia Caused by Pantoea stewartii Subspecies indologenes, Australia.” Emerging infectious diseases (2025). PMID: 39983690 ↗
L4CASE_REPORTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [43]
Moon J, Jang Y, Kim N et al.. “Diagnosis of Haemophilus influenzae Pneumonia by Nanopore 16S Amplicon Sequencing of Sputum.” Emerging infectious diseases (2018). PMID: 29989532 ↗
L4CASE_REPORTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [44]
Vaughn VM, Dickson RP, Horowitz JK et al.. “Community-Acquired Pneumonia: A Review.” JAMA (2024). PMID: 39283629 ↗
L5REVIEW_NARRATIVECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon - [45]
Pirracchio R, Venkatesh B, Legrand M. “Low-Dose Corticosteroids for Critically Ill Adults With Severe Pulmonary Infections: A Review.” JAMA (2024). PMID: 38865154 ↗
L5REVIEW_NARRATIVECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon - [46]
Rhodes NJ, Rohani R, Yarnold PR et al.. “Machine Learning To Stratify Methicillin-Resistant Staphylococcus aureus Risk among Hospitalized Patients with Community-Acquired Pneumonia.” Antimicrobial agents and chemotherapy (2022). PMID: 36472425 ↗
L5OTHERCited in: Bottom Line, Current Evidence and Standard, On the Horizon - [47]
Wicha WW, Henson C, Webbley K et al.. “Tissue Distribution of [14C]-Lefamulin into the Urogenital Tract in Rats.” Antimicrobial agents and chemotherapy (2022). PMID: 35862748 ↗
L5OTHERCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [48]
File TM, Ramirez JA, Wilde AM. “New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus).” Antimicrobial agents and chemotherapy (2025). PMID: 39817764 ↗
L5REVIEW_NARRATIVECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [49]
Oliver MB, Fong K, Certain L et al.. “Validation of a Community-Acquired Pneumonia Score To Improve Empiric Antibiotic Selection at an Academic Medical Center.” Antimicrobial agents and chemotherapy (2021). PMID: 33257449 ↗
L5OTHERCited in: Bottom Line, Current Evidence and Standard - [50]
Zheng Y, Liu SP, Xu BP et al.. “Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia.” Antimicrobial agents and chemotherapy (2018). PMID: 29941652 ↗
L5OTHERCited in: Bottom Line, Current Evidence and Standard - [51]
Paukner S, Gelone SP, Arends SJR et al.. “Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016).” Antimicrobial agents and chemotherapy (2019). PMID: 30670415 ↗
L5OTHERCited in: Bottom Line, Current Evidence and Standard - [52]
Falcone M, Russo A, Shindo Y et al.. “A Hypothesis-Generating Study of the Combination of Aspirin plus Macrolides in Patients with Severe Community-Acquired Pneumonia.” Antimicrobial agents and chemotherapy (2019). PMID: 30509940 ↗
L5OTHERCited in: Bottom Line, Current Evidence and Standard - [53]
Malinis M, Abbo L, Vazquez JA et al.. “Community-acquired pneumonia: a US perspective on the guideline gap.” The Journal of antimicrobial chemotherapy (2024). PMID: 38693426 ↗
L5OTHERCited in: Bottom Line, Current Evidence and Standard, On the Horizon - [54]
Roger C, Allaouchiche B, Quintão De Moraes D et al.. “Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia.” The Journal of antimicrobial chemotherapy (2025). PMID: 40754699 ↗
L5OTHERCited in: Bottom Line, Current Evidence and Standard - [55]
Viasus D, Simonetti AF, Garcia-Vidal C et al.. “Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia.” The Journal of antimicrobial chemotherapy (2016). PMID: 27798219 ↗
L5OTHERCited in: Bottom Line, Current Evidence and Standard - [56]
Greco Kinney A, Kovacic Scherrer N, Sarkar S et al.. “β-Lactams plus doxycycline versus azithromycin for treatment of severe community-acquired pneumonia in critically ill patients.” The Journal of antimicrobial chemotherapy (2023). PMID: 37814829 ↗
L5OTHERCited in: Bottom Line, Current Evidence and Standard, On the Horizon - [57]
Boutzoukas AE, Mackow N, Giri A et al.. “Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections.” The Journal of antimicrobial chemotherapy (2024). PMID: 39236214 ↗
L5OTHERCited in: Bottom Line, Current Evidence and Standard, On the Horizon - [58]
Rodvold KA. “Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin.” The Journal of antimicrobial chemotherapy (2019). PMID: 30949709 ↗
L5OTHERCited in: Bottom Line, Current Evidence and Standard - [59]
Cantón R, Akova M, Langfeld K et al.. “Relevance of the Consensus Principles for Appropriate Antibiotic Prescribing in 2022.” The Journal of antimicrobial chemotherapy (2022). PMID: 36065724 ↗
L5OTHERCited in: Bottom Line, Current Evidence and Standard - [60]
Sazawal S, Black RE. “Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials.” The Lancet. Infectious diseases (2003). PMID: 12954560 ↗
L2SR_OBSCited in: Background: Evolution of Treatment - [61]
Zhong NS, Sun T, Zhuo C et al.. “Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial.” The Lancet. Infectious diseases (2014). PMID: 25539586 ↗
L1RCTCited in: Background: Evolution of Treatment - [62]
Contopoulos-Ioannidis DG, Ioannidis JP, Chew P et al.. “Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections.” The Journal of antimicrobial chemotherapy (2001). PMID: 11679558 ↗
L1SR_MA_RCTCited in: Background: Evolution of Treatment - [63]
Bonten MJ, Huijts SM, Bolkenbaas M et al.. “Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.” The New England journal of medicine (2015). PMID: 25785969 ↗
L1RCTCited in: Background: Evolution of Treatment - [64]
Blum CA, Nigro N, Briel M et al.. “Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.” Lancet (London, England) (2015). PMID: 25608756 ↗
L1RCTCited in: Background: Evolution of Treatment - [65]
Siempos II, Vardakas KZ, Kopterides P et al.. “Adjunctive therapies for community-acquired pneumonia: a systematic review.” The Journal of antimicrobial chemotherapy (2008). PMID: 18641037 ↗
L2SR_OBSCited in: Background: Evolution of Treatment - [66]
Oosterheert JJ, Bonten MJ, Hak E et al.. “How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review.” The Journal of antimicrobial chemotherapy (2003). PMID: 12972448 ↗
L2SR_OBSCited in: Background: Evolution of Treatment - [67]
Torres A, Sibila O, Ferrer M et al.. “Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial.” JAMA (2015). PMID: 25688779 ↗
L1RCTCited in: Background: Evolution of Treatment - [68]
Rubino CM, Bhavnani SM, Forrest A et al.. “Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia.” Antimicrobial agents and chemotherapy (2011). PMID: 21968360 ↗
L1RCTCited in: Background: Evolution of Treatment - [69]
Drehobl M, Bianchi P, Keyserling CH et al.. “Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia.” Antimicrobial agents and chemotherapy (1997). PMID: 9210689 ↗
L1RCTCited in: Background: Evolution of Treatment - [70]
Dean NC, Sperry P, Wikler M et al.. “Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care.” Antimicrobial agents and chemotherapy (2006). PMID: 16569825 ↗
L1RCTCited in: Background: Evolution of Treatment - [71]
Marrie TJ. “Community-acquired pneumonia in the elderly.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2000). PMID: 11049791 ↗
L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment - [72]
Hidron AI, Low CE, Honig EG et al.. “Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia.” The Lancet. Infectious diseases (2009). PMID: 19467478 ↗
L4CASE_REPORTCited in: Background: Evolution of Treatment - [73]
Barlow GD, Lamping DL, Davey PG et al.. “Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers.” The Lancet. Infectious diseases (2003). PMID: 12901890 ↗
L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment - [74]
Principi N, Esposito S. “Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory-tract infections.” The Lancet. Infectious diseases (2001). PMID: 11871806 ↗
L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment - [75]
Chertow DS, Memoli MJ. “Bacterial coinfection in influenza: a grand rounds review.” JAMA (2013). PMID: 23321766 ↗
L4CASE_REPORTCited in: Background: Evolution of Treatment - [76]
Gordin FM, Masur H. “Current approaches to tuberculosis in the United States.” JAMA (2012). PMID: 22797646 ↗
L4CASE_REPORTCited in: Background: Evolution of Treatment - [77]
Prina E, Ranzani OT, Torres A. “Community-acquired pneumonia.” Lancet (London, England) (2015). PMID: 26277247 ↗
L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment - [78]
Ruuskanen O, Lahti E, Jennings LC et al.. “Viral pneumonia.” Lancet (London, England) (2011). PMID: 21435708 ↗
L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment - [79]
File TM. “Community-acquired pneumonia.” Lancet (London, England) (2003). PMID: 14683661 ↗
L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment - [80]
Brown PD, Lerner SA. “Community-acquired pneumonia.” Lancet (London, England) (1998). PMID: 9788476 ↗
L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment - [81]
Bastida T, Pérez-Vázquez M, Campos J et al.. “Levofloxacin treatment failure in Haemophilus influenzae pneumonia.” Emerging infectious diseases (2003). PMID: 14718097 ↗
L4CASE_REPORTCited in: Background: Evolution of Treatment - [82]
Gleason PP, Kapoor WN, Stone RA et al.. “Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia.” JAMA (1997). PMID: 9207335 ↗
L5OTHERCited in: Background: Evolution of Treatment - [83]
Micek ST, Kollef KE, Reichley RM et al.. “Health care-associated pneumonia and community-acquired pneumonia: a single-center experience.” Antimicrobial agents and chemotherapy (2007). PMID: 17682100 ↗
L5OTHERCited in: Background: Evolution of Treatment - [84]
Dryden M, Hand K, Davey P. “Antibiotics for community-acquired pneumonia.” The Journal of antimicrobial chemotherapy (2009). PMID: 19820250 ↗
L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment - [85]
Kovaleva A, Remmelts HH, Rijkers GT et al.. “Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review.” The Journal of antimicrobial chemotherapy (2011). PMID: 22190609 ↗
L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment - [86]
Klugman KP, Lonks JR. “Hidden epidemic of macrolide-resistant pneumococci.” Emerging infectious diseases (2005). PMID: 15963272 ↗
L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment - [87]
Blair JE, Chang YH, Cheng MR et al.. “Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis.” Emerging infectious diseases (2014). PMID: 24865953 ↗
L5OTHERCited in: Background: Evolution of Treatment - [88]
Valdivia L, Nix D, Wright M et al.. “Coccidioidomycosis as a common cause of community-acquired pneumonia.” Emerging infectious diseases (2006). PMID: 16707052 ↗
L5OTHERCited in: Background: Evolution of Treatment - [89]
MacDougall C, Guglielmo BJ, Maselli J et al.. “Antimicrobial drug prescribing for pneumonia in ambulatory care.” Emerging infectious diseases (2005). PMID: 15757551 ↗
L5OTHERCited in: Background: Evolution of Treatment - [90]
Watkins RR, File TM. “Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 32221520 ↗
L5REVIEW_NARRATIVECited in: Current Evidence and Standard - [91]
Hojat LS, Laguio-Vila MR, Sullivan LR et al.. “We Dissent: Lessons From the 2025 Community-Acquired Pneumonia Guidelines.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41340515 ↗
L5OTHERCited in: Current Evidence and Standard - [92]
Stotts C, Corrales-Medina VF, deKemp RA et al.. “Targeting Vascular Inflammation In Patients with Community-Acquired Pneumonia (TIN-CAP): protocol for a multicentre, randomised, double-blind, placebo-controlled trial.” BMJ open (2026). PMID: 41781043 ↗
L2TRIAL_NONRANDOMCited in: Current Evidence and Standard - [93]
Lepak AJ, Zhao M, Marchillo K et al.. “In Vivo Pharmacodynamic Evaluation of Omadacycline against Staphylococcus aureus in the Neutropenic Mouse Pneumonia Model.” Antimicrobial agents and chemotherapy (2020). PMID: 31712210 ↗
L5OTHERCited in: Current Evidence and Standard - [94]
MacLauchlin C, Schneider SE, Keedy K et al.. “Metabolism, Excretion, and Mass Balance of Solithromycin in Humans.” Antimicrobial agents and chemotherapy (2018). PMID: 29507061 ↗
L5OTHERCited in: Current Evidence and Standard - [95]
Torumkuney D, Kundu S, Vu GV et al.. “Country data on AMR in Vietnam in the context of community-acquired respiratory tract infections: links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicines and clinical outcome.” The Journal of antimicrobial chemotherapy (2022). PMID: 36065731 ↗
L5OTHERCited in: Current Evidence and Standard - [96]
Torumkuney D, de la Torre C, Langfeld K et al.. “Country data on AMR in Mexico in the context of community-acquired respiratory tract infections: links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicine and clinical outcome.” The Journal of antimicrobial chemotherapy (2022). PMID: 36065728 ↗
L5OTHERCited in: Current Evidence and Standard - [97]
Klein EY, Mojica N, Jiang W et al.. “Trends in Methicillin-Resistant Staphylococcus aureus Hospitalizations in the United States, 2010-2014.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2017). PMID: 29020322 ↗
L5OTHERCited in: Applicability and Caveats - [98]
Butler AM, Nickel KB, Olsen MA et al.. “Comparative Safety of Different Antibiotic Regimens for the Treatment of Outpatient Community-Acquired Pneumonia Among Otherwise Healthy Adults.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 39442057 ↗
L5OTHERCited in: Applicability and Caveats - [99]
Smith DJ, Free RJ, Thompson GR et al.. “Clinical Testing Guidance for Coccidioidomycosis, Histoplasmosis, and Blastomycosis in Patients With Community-Acquired Pneumonia for Primary and Urgent Care Providers.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37802909 ↗
L5OTHERCited in: Applicability and Caveats, On the Horizon - [100]
Christensen MA, Nevers M, Ying J et al.. “Simulated Adoption of 2019 Community-Acquired Pneumonia Guidelines Across 114 Veterans Affairs Medical Centers: Estimated Impact on Culturing and Antibiotic Selection in Hospitalized Patients.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33512530 ↗
L5OTHERCited in: Applicability and Caveats - [101]
Yi SH, Hatfield KM, Baggs J et al.. “Duration of Antibiotic Use Among Adults With Uncomplicated Community-Acquired Pneumonia Requiring Hospitalization in the United States.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2018). PMID: 29126268 ↗
L5OTHERCited in: Applicability and Caveats - [102]
Vaughn VM, Ratz D, Greene MT et al.. “Antibiotic Stewardship Strategies and Their Association With Antibiotic Overuse After Hospital Discharge: An Analysis of the Reducing Overuse of Antibiotics at Discharge (Road) Home Framework.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 35143638 ↗
L5OTHERCited in: Applicability and Caveats - [103]
Kurotschka PK, Bentivegna M, Hulme C et al.. “Identifying the Best Initial Oral Antibiotics for Adults with Community-Acquired Pneumonia: A Network Meta-Analysis.” Journal of general internal medicine (2024). PMID: 38360961 ↗
L2SR_OBSCited in: Applicability and Caveats - [104]
Furukawa Y, Luo Y, Funada S et al.. “Optimal duration of antibiotic treatment for community-acquired pneumonia in adults: a systematic review and duration-effect meta-analysis.” BMJ open (2023). PMID: 36948555 ↗
L2SR_OBSCited in: Applicability and Caveats - [105]
R Marques I, P Calvi I, A Cruz S et al.. “Shorter versus longer duration of Amoxicillin-based treatment for pediatric patients with community-acquired pneumonia: a systematic review and meta-analysis.” European journal of pediatrics (2022). PMID: 36066660 ↗
L2SR_OBSCited in: Applicability and Caveats - [106]
Williams DJ, Creech CB, Walter EB et al.. “Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial.” JAMA pediatrics (2022). PMID: 35040920 ↗
L1RCTCited in: Applicability and Caveats - [107]
Israelsen SB, Tingsgård S, Thorlacius-Ussing L et al.. “Short-course antibiotic therapy of 5 days in community-acquired pneumonia (CAP5): study protocol for a randomised controlled trial.” BMJ open (2023). PMID: 37479519 ↗
L2TRIAL_NONRANDOMCited in: Applicability and Caveats - [108]
Ding HF, Li F, Xu YX et al.. “Changes in inflammatory markers and efficacy analysis of continuous subcutaneous insulin infusion in senior patients with type 2 diabetes mellitus hospitalized with community-acquired pneumonia: a randomized controlled trial.” European geriatric medicine (2024). PMID: 38194052 ↗
L1RCTCited in: Applicability and Caveats - [109]
Torumkuney D, Kozlov R, Sidorenko S et al.. “Country data on AMR in Russia in the context of community-acquired respiratory tract infections: links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicine and clinical outcome.” The Journal of antimicrobial chemotherapy (2022). PMID: 36065732 ↗
L5OTHERCited in: Applicability and Caveats - [110]
Bergmann F, Pracher L, Sawodny R et al.. “Efficacy and Safety of Corticosteroid Therapy for Community-Acquired Pneumonia: A Meta-Analysis and Meta-Regression of Randomized, Controlled Trials.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37876267 ↗
L2SR_OBSCited in: On the Horizon - [111]
Gasoyan H, Deshpande A, Imrey PB et al.. “Potential Implications of Using Locally Validated Risk Factors for Drug-Resistant Pathogens in Patients With Community-Acquired Pneumonia in US Hospitals: A Cross-Sectional Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 39226148 ↗
L5OTHERCited in: On the Horizon - [112]
Ho EC, Olson KE, Butler M et al.. “Clinical Impact of Pleural Fluid Streptococcus pneumoniae Polymerase Chain Reaction Testing in Children With Complicated Pneumonia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 39207213 ↗
L5OTHERCited in: On the Horizon - [113]
Eynath Y, McNeil R, Buchrits S et al.. “Chloramphenicol versus ceftriaxone for the treatment of pneumonia and sepsis in elderly patients with advanced dementia and functional disability. A propensity-weighted retrospective cohort study.” The Journal of antimicrobial chemotherapy (2024). PMID: 39308334 ↗
L3COHORTCited in: On the Horizon - [114]
Prizão VM, Martins OC, de Hollanda Morais BAA et al.. “Effectiveness of macrolides as add-on therapy to beta-lactams in community-acquired pneumonia: A meta-analysis of randomized controlled trials.” European journal of clinical pharmacology (2024). PMID: 39551892 ↗
L1SR_MA_RCTCited in: On the Horizon - [115]
Donà D, Brigadoi G, Grandinetti R et al.. “Treatment of mild to moderate community-acquired pneumonia in previously healthy children: an Italian intersociety consensus (SIPPS-SIP-SITIP-FIMP-SIAIP-SIMRI-FIMMG-SIMG).” Italian journal of pediatrics (2024). PMID: 39427174 ↗
L2SR_OBSCited in: On the Horizon - [116]
Akinosoglou K, Leventogiannis K, Tasouli E et al.. “Clarithromycin for improved clinical outcomes in community-acquired pneumonia: A subgroup analysis of the ACCESS trial.” International journal of antimicrobial agents (2024). PMID: 39647798 ↗
L1RCTCited in: On the Horizon - [117]
Cantais A, Pillet S, Rigaill J et al.. “Impact of respiratory pathogens detection by a rapid multiplex polymerase chain reaction assay on the management of community-acquired pneumonia for children at the paediatric emergency department. A randomized controlled trial, the Optimization of Pneumonia Acute Care (OPTIPAC) study.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2024). PMID: 39111697 ↗
L1RCTCited in: On the Horizon - [118]
Li Y, Zhu D, Sun S et al.. “A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients.” International journal of antimicrobial agents (2024). PMID: 38851462 ↗
L1RCTCited in: On the Horizon - [119]
Kok HC, McCallum GB, Yerkovich ST et al.. “Twenty-four Month Outcomes of Extended- Versus Standard-course Antibiotic Therapy in Children Hospitalized With Pneumonia in High-risk Settings: A Randomized Controlled Trial.” The Pediatric infectious disease journal (2024). PMID: 38830139 ↗
L1RCTCited in: On the Horizon - [120]
Dinh A, Duran C, Ropers J et al.. “Exclusive oral antibiotic treatment for hospitalized community-acquired pneumonia: a post-hoc analysis of a randomized clinical trial.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2024). PMID: 38734138 ↗
L1RCTCited in: On the Horizon - [121]
Markussen DL, Wathne JS, Ritz C et al.. “Determinants of non-adherence to antibiotic treatment guidelines in hospitalized adults with suspected community-acquired pneumonia: a prospective study.” Antimicrobial resistance and infection control (2024). PMID: 39580437 ↗
L2TRIAL_NONRANDOMCited in: On the Horizon - [122]
Paukner S, Mendes RE, Arends SJR et al.. “7-Year (2015-21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms.” The Journal of antimicrobial chemotherapy (2024). PMID: 38113528 ↗
L5OTHERCited in: On the Horizon - [123]
van Os W, Zeitlinger M. “Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections.” The Journal of antimicrobial chemotherapy (2024). PMID: 38174805 ↗
L5OTHERCited in: On the Horizon